Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride

Analyse the glucose profile, based on continuous glucose monitoring by CGMS, in type 2 diabetics inadequately controlled by metformin, before and after the addition of Glimepiride.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

35 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Sanofi-Aventis

Paris, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men or women aged 35 to 70 years
Having given their consent
Type 2 diabetics (HBA1c greater than 6.5%
Fasting glycaemia greater than 1.40 g/l) not controlled by Metformin for at least 6 weeks.

Treatment and study plan

Glimepiride

Drug

Primary outcomes

Change in interstitial glucose levels between the observation and maintenance phases.

Time frame: The mean of 24 variations in average hourly glucose readings recorded by CGMS.

Secondary outcomes

HbA1c and fasting blood glucose levels.

Time frame: Measured in the observation and maintenance phases, and change between the two phases.

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Important dates

Study start: 2002
Study completion: 2003
First posted: Mar 12, 2008
Registry last updated: Mar 28, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed